Peplin into Phase III
Tuesday, 09 September, 2008
Peplin [ASX: PLI] has begun a Phase III trial of its PEP005 gel for solar keratoses, common pre-cancerous skin lesions.
The trial will examine the efficacy of the gel when applied to locations other than the head. It will be simultaneously conducted in sites in Australia and the US.
The trial is being conducted with a Special Protocol Assessment from the US FDA, which ensures that the results of the study may be submitted to the FDA as part of the basis of a new drug application.
Around 250 participants are expected take part in the trial of PEP005, an ingenol mebutate gel.
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
Space conditions can lead to periodontitis, scientists say
Living in zero gravity can lead to periodontitis — a serious condition where the gums...
